Latest Breaking News On - Tscan hematologic malignancies program - Page 1 : comparemela.com

WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE)  TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the.

United statesHeather savelleJoyce allaireLifesci advisorsColumbia university medical centerErnestn morial convention centerTscan hematologic malignancies programAmerican society of hematologyTscan therapeutics incSecurities exchangeAmerican societyAnnual meetingEran reshefColumbia university medicalEarly phaseInvestigational therapies